SAN ANTONIO — In this exclusive video from the American College of Gastroenterology Annual Meeting, Mark Pimentel, MD, executive director of the Medically Associated Science and Technology (MAST) program at Cedars-Sinai, discusses his presentation on the role of the gut microbiome in irritable bowel syndrome.
“We now know that a good portion of irritable bowel syndrome is derived from the microbiome,” Pimentel told Healio Gastroenterology and Liver Disease. “In fact, we now know, you could argue, more about the cause of IBS than we do inflammatory bowel disease, because we know that approximately in 60%, maybe even 70%, of patients food poisoning may have been the trigger for the development of IBS.”
Discovering the trigger for IBS in the microbiome has led to a lot of new research and discoveries in the field, Pimentel said.
Among those discoveries is a breath test that can predict response to treatment with Xifaxan (rifaximin, Salix), which was part of Pimentel’s talk at the postgraduate course.
Pimentel M. The Microbiome and Its Role in IBS. Presented at: American College of Gastroenterology Annual Meeting; Oct. 25-30, 2019; San Antonio.
Disclosures: Pimentel reports financial ties to Allergan, Gemelli Biotech, Naia Pharmaceuticals, Salix, Shire, Synthetic Biologics and U.S. Medical.